J&J takes over Covid vaccine plant in US after 15 million doses were wasted

A pharmaceutical factory that produced ingredients for the Covid-19 vaccines developed by both AstraZeneca and Johnson & Johnson will exclusively supply the latter company after a workers error there that wasted millions of doses.

J&J based in the United States said he “took full responsibility” for the Baltimore plant owned by Emergent BioSolutions. AstraZeneca based in UK said it would move the production of Covid-19 vaccines out of the facility to another location.

Doses of 15 million J&J vaccines reported have been reported to be ruined last week, after workers at the Baltimore plant accidentally mixed ingredients for his jab and the Oxford / AstraZeneca jab.

The mistake was a setback in efforts to instill confidence in people who are suspicious of the news vaccines developed to fight a virus that has killed more than 550,000 people in the United States.

J&J said last week it identified a batch of the drug substance that did not meet the quality standards of the plant owned by Emergent, a New York-listed life sciences company.

In an update over the weekend, J&J said he was increasing the ranks of manufacturing, quality and technical operations staff to work at the Baltimore plant as he took responsibility for his vaccine production there.

Yet J&J reiterated its intention to deliver nearly 100 million doses of its vaccine to the US government by the end of May. The United States has fully immunized 61 million people, of which 4 million were J & J’s single-dose vaccine, according to at the Centers for Disease Control and Prevention.

The Emergent plant in Baltimore has yet to get emergency clearance from the U.S. Food and Drug Administration to manufacture substances for the vaccine, and J&J has said it will work towards that.

AstraZeneca said it was working with the federal government to implement plans to produce its vaccine in the United States. “As part of this effort, and in full cooperation with the US government, AstraZeneca will relocate production” of its vaccine drug substance from the Emergent facility, he said.

The measures came after the Biden administration put J&J in charge of the Baltimore plant and decided to block it from making the Oxford / AstraZeneca vaccine, The New York Times reported, citing senior federal health officials.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *